Intracerebroventricular injection of H19 siRNA reduces infarct volume and brain edema, decreases tumor necrosis factor-α and interleukin-1β levels in brain tissue and plasma, and increases plasma interleukin-10 levels 24 h post-stroke. This evidence concerns the gene H19 and stroke disorder.